GT Biopharma, Inc. (GTBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200K 400K 600K Q4 '10: 11K Q1 '11: 31K Q2 '11: 32K Q3 '11: 34K Q4 '11: 26K Q1 '12: 7K Q2 '12: 7K Q3 '12: 125K Q4 '12: 341K Q1 '13: 428K Q2 '13: 483K Q3 '13: 546K Q4 '13: 368K Q1 '14: 280K Q2 '14: 249K Q3 '14: 69K Q4 '14: 61K Q1 '15: 68K Q2 '15: 63K Q3 '15: 60K Q4 '15: 27K Q1 '16: 20K Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '11 Q1 '13 Q2 '14 Q3 '15 Q4 '16 Q1 '18 Q3 '21

Gross Profit TTM

-150K 0 150K 300K 450K Q4 '10: -54K Q1 '11: -59K Q2 '11: -73K Q3 '11: -79K Q4 '11: -22K Q1 '12: -17K Q2 '12: -2K Q3 '12: 92K Q4 '12: 247K Q1 '13: 266K Q2 '13: 309K Q3 '13: 281K Q4 '13: 142K Q1 '14: 123K Q2 '14: 87K Q3 '14: 25K Q4 '14: 4K Q1 '15: 11K Q2 '15: 23K Q3 '15: 25K Q4 '15: 27K Q1 '16: 20K Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q2 '11 Q2 '12 Q2 '13 Q2 '14 Q2 '15 Q2 '16 Q2 '17 Q2 '18

Operating Income TTM

-270M -180M -90M 0 90M 180M 270M Q4 '10: -2.5M Q1 '11: -3.4M Q2 '11: -3.5M Q3 '11: -3.4M Q4 '11: -3.9M Q1 '12: -2.5M Q2 '12: -3M Q3 '12: -3.8M Q4 '12: -3.5M Q1 '13: -3.5M Q2 '13: -2.5M Q3 '13: -1.3M Q4 '13: -793K Q1 '14: -547K Q2 '14: -577K Q3 '14: -986K Q4 '14: -2.4M Q1 '15: -4.1M Q2 '15: -5.4M Q3 '15: -7.7M Q4 '15: -8.9M Q1 '16: -11M Q2 '16: -11.7M Q3 '16: -11.5M Q4 '16: -9.4M Q1 '17: -7M Q2 '17: -6.2M Q3 '17: -130.5M Q4 '17: -135.6M Q1 '18: -141.2M Q2 '18: -145.1M Q3 '18: -252.9M Q4 '18: -250.1M Q1 '19: -247M Q2 '19: -244.1M Q3 '19: -18.3M Q4 '19: 16.1M Q1 '20: 21.2M Q2 '20: 21.9M Q3 '20: 28.8M Q4 '20: -4.6M Q1 '21: -34.7M Q2 '21: -37.5M Q3 '21: -41.5M Q4 '21: -57.5M Q1 '22: -34M Q2 '22: -32.6M Q3 '22: -33.7M Q4 '22: -21.3M Q1 '23: -19.5M Q2 '23: -20.1M Q3 '23: -16.2M Q4 '23: -13.6M Q1 '24: -13M Q2 '24: -13.3M Q3 '24: -13.8M Q4 '24: -14.4M Q1 '25: -13.2M Q2 '25: -10.8M Q3 '25: -10.6M Q4 '25: -12.4M Q1 '26: -13.3M Q2 '26: -16.3M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-270M -180M -90M 0 90M 180M 270M Q4 '10: -3M Q1 '11: -2.8M Q2 '11: -3.9M Q3 '11: -3.2M Q4 '11: -3.7M Q1 '12: -2.4M Q2 '12: -4.1M Q3 '12: -5.5M Q4 '12: -5.2M Q1 '13: -4.1M Q2 '13: -2M Q3 '13: -918K Q4 '13: -511K Q1 '14: -1.4M Q2 '14: -1.3M Q3 '14: -5.2M Q4 '14: -23.5M Q1 '15: -43.6M Q2 '15: -16.5M Q3 '15: -14M Q4 '15: -21.5M Q1 '16: 13.7M Q2 '16: -11.6M Q3 '16: -13.5M Q4 '16: 9.8M Q1 '17: -10M Q2 '17: -14M Q3 '17: -141M Q4 '17: -144.2M Q1 '18: -149.2M Q2 '18: -155.8M Q3 '18: -261M Q4 '18: -259.2M Q1 '19: -253.6M Q2 '19: -247.3M Q3 '19: -41.4M Q4 '19: -38.6M Q1 '20: -35.8M Q2 '20: -50.5M Q3 '20: -23.5M Q4 '20: -13.4M Q1 '21: -41.3M Q2 '21: -28.8M Q3 '21: -31.3M Q4 '21: -58M Q1 '22: -33.8M Q2 '22: -31.9M Q3 '22: -33.3M Q4 '22: -20.9M Q1 '23: -15.7M Q2 '23: -14.7M Q3 '23: -10.2M Q4 '23: -7.6M Q1 '24: -9.6M Q2 '24: -11.4M Q3 '24: -12.3M Q4 '24: -13.2M Q1 '25: -11.7M Q2 '25: -38.1M Q3 '25: -26.4M Q4 '25: -30.2M Q1 '26: -32.2M Q2 '26: -6.6M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 100K 200K 300K Q4 '10: 65K Q1 '11: 90K Q2 '11: 105K Q3 '11: 113K Q4 '11: 48K Q1 '12: 24K Q2 '12: 9K Q3 '12: 33K Q4 '12: 94K Q1 '13: 162K Q2 '13: 174K Q3 '13: 265K Q4 '13: 226K Q1 '14: 157K Q2 '14: 162K Q3 '14: 44K Q4 '14: 57K Q1 '15: 57K Q2 '15: 40K Q3 '15: 35K Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q2 '11 Q2 '12 Q2 '13 Q2 '14 Q2 '15 Q2 '16 Q2 '17 Q2 '18

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q2 '11: -1.3M Q3 '11: -1M Q4 '11: -963K Q1 '12: -1M Q2 '12: -918K Q3 '12: -1.1M Q4 '12: -987K Q1 '13: -933K Q2 '13: -610K Q3 '13: -287K Q4 '13: -442K Q1 '14: -394K Q2 '14: -457K Q3 '14: -1.1M Q4 '14: -1.7M Q1 '15: -3.4M Q2 '15: -4.7M Q3 '15: -4.8M Q4 '15: -4.7M Q1 '16: -3M Q2 '16: -2.8M Q3 '16: -2.7M Q4 '16: -1.9M Q1 '17: -2.4M Q2 '17: -1.7M Q3 '17: -3.4M Q4 '17: -5.4M Q1 '18: -9M Q2 '18: -10.4M Q3 '18: -11.6M Q4 '18: -10.7M Q1 '19: -7.4M Q2 '19: -6.7M Q3 '19: -4.4M Q4 '19: -3.7M Q1 '20: -2.9M Q2 '20: -5.2M Q3 '20: -5.8M Q4 '20: -7.3M Q1 '21: -10.7M Q2 '21: -11.6M Q3 '21: -13.8M Q4 '21: -15.6M Q1 '22: -17.1M Q2 '22: -15.6M Q3 '22: -14.6M Q4 '22: -15.2M Q1 '23: -12.9M Q2 '23: -12.1M Q3 '23: -11.1M Q4 '23: -8.9M Q1 '24: -10.1M Q2 '24: -11.7M Q3 '24: -12.5M Q4 '24: -12.9M Q1 '25: -10.9M Q2 '25: -10.4M Q3 '25: -11.4M Q4 '25: -12.9M Q1 '26: -13.2M Q2 '26: -14.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-12M -8M -4M 0 4M 8M 12M Q4 '17: -5.4M Q1 '18: -9M Q2 '18: -10.4M Q3 '18: -11.6M Q4 '18: -10.7M Q1 '19: -7.4M Q2 '19: -6.8M Q3 '19: -4.5M Q4 '19: -3.7M Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

-250M 0 250M 500M 750M Q1 '12: 283M Q2 '12: 329.3M Q1 '13: 717.7M Q2 '13: 573.1M Q1 '14: 573.1M Q2 '14: 573.1M Q3 '14: 590.1M Q1 '15: 2.4M Q2 '15: 4.9M Q3 '15: 2.4M Q1 '16: 17.4M Q2 '16: 25.4M Q3 '16: 27.5M Q1 '17: 191.8K Q2 '17: -5.14 Q3 '17: 16M Q1 '18: 50.1M Q2 '18: -0.18 Q3 '18: 50.2M Q1 '19: 51.1M Q1 '20: 70.1M Q1 '21: 16.2M Q2 '21: 33.5M Q3 '21: 31.4M Q1 '22: 32.5M Q2 '22: 31.2M Q3 '22: 31.4M Q1 '23: 1.1M Q2 '23: 1.3M Q3 '23: 1.4M Q1 '24: 1.4M Q2 '24: 1.7M Q3 '24: 2.2M Q1 '25: 2.3M Q2 '25: 2.8M Q3 '25: 3.9M Q1 '26: 30.3M Q2 '26: 38.8M Q1 '13 Q1 '15 Q3 '16 Q2 '18 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-50.00 0.00 50.00 100.00 150.00 Q4 '10: -0.03 Q1 '11: -0.01 Q2 '11: -0.01 Q3 '11: -0.02 Q4 '11: -0.02 Q1 '12: -0.01 Q2 '12: -0.02 Q3 '12: -0.02 Q4 '12: -0.01 Q1 '13: -0.01 Q2 '13: 0.00 Q3 '13: 0.00 Q4 '13: -0.01 Q1 '14: -0.01 Q2 '14: -0.01 Q3 '14: -0.02 Q4 '14: -0.04 Q1 '15: -8.65 Q2 '15: -3.18 Q3 '15: -2.46 Q4 '15: -12.37 Q1 '16: -2.92 Q2 '16: -8.33 Q3 '16: -8.91 Q4 '16: 120.38 Q1 '17: 93.18 Q2 '19: -4.91 Q3 '19: -0.72 Q4 '20: -10.93 Q1 '21: -12.74 Q2 '21: -8.77 Q3 '21: -8.30 Q4 '21: -2.67 Q1 '22: -1.01 Q2 '22: -0.96 Q3 '22: -1.01 Q4 '22: -19.67 Q1 '23: -19.71 Q2 '23: -21.10 Q3 '23: -22.65 Q4 '23: -5.64 Q1 '24: -7.07 Q2 '24: -7.75 Q3 '24: -7.51 Q4 '24: -7.00 Q1 '25: -5.69 Q2 '25: -14.44 Q3 '25: -11.87 Q4 '25: -6.68 Q1 '26: -6.46 Q2 '26: 4.34 Q1 '11 Q4 '12 Q3 '14 Q2 '16 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.